In patients with MYC-rearranged aggressive B-cell lymphomas, the currently available data suggests that DA-EPOCH-R has a relatively higher response rate and in some instances with improved survival 13. This evidence concerns the gene MYC and B-cell non-Hodgkin lymphoma.